Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma

NCT05122546 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05122546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05122546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 1, 2021
Completion date
January 12, 2027
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma, advanced papillary renal cell carcinoma, advanced renal cell carcinoma, advanced sarcomatoid renal cell carcinoma, metastatic clear cell renal cell carcinoma, metastatic papillary renal cell carcinoma, metastatic renal cell carcinoma, metastatic sarcomatoid renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8, unresectable clear cell renal cell carcinoma, unresectable renal cell carcinoma